VEGF Imaging in Renal Cell Carcinoma

Inclusion criteria: * locally advanced irresectable or metastatic renal cell cancer * no untreated brain metastases (CT or MRI not necessary in the absence of symptoms) * no uncontrolled hypertension * no clinically significant cardiovascular events or disease during the last 12 months * no surgery in the last 4 weeks * no treatment with bevacizumab or another monoclonal antibody with anti-angiogenic properties in the last 4 months * no treatment with a tyrosine kinase inhibitor during the last 4 weeks * measurable disease with x-ray or CT scan, at least one site of disease must be unidimensionally measurable as follows: X-ray \> 20 mm, Spiral CT scan \> 10 mm, non-spiral CT scan \> 20 mm * clear cell histology component * not pregnant or nursing * women of childbearing potential must use effective contraception * absence of any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be discussed with the patient before registration in the trial * before patient randomization, written informed consent must be given according to GCP, and local regulations